Breast health

Tamoxifen vs Raloxifene: Weighing Risk Reducers

Save

Tamoxifen and raloxifene are selective estrogen receptor modulators that reduce breast cancer risk. In the STAR trial, raloxifene was about as effective as tamoxifen at preventing invasive breast cancer, with fewer blood clots and uterine cancers. Tamoxifen suits premenopausal and postmenopausal women; raloxifene is for postmenopausal women and also protects bone.

Last updated: July 2026

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

Tamoxifen vs raloxifene: what is the difference?

Tamoxifen and raloxifene are both selective estrogen receptor modulators (SERMs) that lower breast cancer risk, but they fit different women. The head-to-head Study of Tamoxifen and Raloxifene (STAR) compared the two in postmenopausal women at increased risk 1. Tamoxifen has the broader use: the earlier NSABP P-1 trial enrolled both premenopausal and postmenopausal women and set tamoxifen's benchmark for prevention 2. Raloxifene's prevention evidence, by contrast, comes only from postmenopausal women, which is why it is not used before menopause. Both block estrogen in breast tissue but behave differently in the uterus, bones, and blood vessels. Before comparing them, it helps to understand when a breast lump is worth worrying about and how risk is assessed.

Which one prevents more breast cancer?

In the STAR trial, the two drugs reduced invasive breast cancer to a broadly similar degree. Raloxifene was about as effective as tamoxifen at preventing invasive breast cancer in postmenopausal women, and longer follow-up has refined that comparison somewhat in tamoxifen's favor 1. For context, tamoxifen's benchmark from the NSABP P-1 prevention trial was a roughly 49% reduction in invasive breast cancer versus placebo 2. Both drugs mainly lower estrogen-receptor-positive cancers rather than receptor-negative disease. The practical takeaway is that efficacy alone rarely decides between them, because the two are close enough that side effects and personal fit usually tip the balance. Absolute benefit still depends on how high a woman's risk is over the next 5 years.

How do the side effects compare?

Safety differences are what most often drive the choice between the two SERMs. In STAR, raloxifene caused fewer blood clots and fewer uterine cancers than tamoxifen, while both raised clot risk compared with no treatment 1. Tamoxifen more commonly causes hot-flash-like symptoms and, unlike raloxifene, is linked to a higher rate of endometrial changes. Raloxifene brings a bonus for some women: it reduces the risk of spinal fractures and is used to treat postmenopausal osteoporosis, in line with osteoporosis treatment guidelines, as shown over 3 years in the MORE trial 3. That bone benefit can make raloxifene attractive for a postmenopausal woman who also has low bone density, which you can read about in osteoporosis risk factors for women over 50.

So which is better for whom?

The better choice depends on menopausal status, whether you have a uterus, and your bone health. A premenopausal woman at high risk is generally a candidate for tamoxifen, since raloxifene has not been studied before menopause 12. A postmenopausal woman, especially one with a uterus or with osteoporosis, may prefer raloxifene's lower clot and uterine risk and its bone protection 13. According to breast cancer risk-assessment guidance, candidacy rests on a formal estimate of breast cancer risk from age, family history, biopsies, and reproductive factors, and inherited risk such as a BRCA change shifts the calculation 45. Protecting bone through midlife is worth reading about in osteoporosis and fracture-risk prevention.

When to weigh these options with a clinician

Choosing a risk-reducing drug is a shared decision that turns on your personal risk and health history. A strong family history, a prior high-risk biopsy, a known genetic change, or a formal risk estimate above the accepted threshold are reasons to seek clinician review of whether tamoxifen or raloxifene fits 4. On either drug, new leg swelling or pain, chest pain, breathlessness, or abnormal vaginal bleeding are reasons to seek prompt medical care, since they can signal a clot or a uterine problem. A gynecologist, breast specialist, or genetic counselor usually guides the comparison alongside your menopause symptoms and bone health. Gale can help you assemble your history and questions beforehand.

Common questions

In the STAR trial, raloxifene was about as effective as tamoxifen at preventing invasive breast cancer in postmenopausal women, and longer follow-up refined the comparison somewhat in tamoxifen's favor. Both mainly reduce estrogen-receptor-positive cancers.

In STAR, raloxifene caused fewer blood clots and fewer uterine cancers than tamoxifen. Both raise clot risk compared with no treatment, so the choice weighs these differences against menopausal status and whether a woman still has a uterus.

No. Raloxifene's prevention evidence comes only from postmenopausal women, so it is not used before menopause. Tamoxifen, by contrast, can be used in both premenopausal and postmenopausal women at elevated risk.

Yes. Raloxifene reduces the risk of spinal fractures and is used to treat postmenopausal osteoporosis. That added bone benefit can make it appealing for a postmenopausal woman who also has low bone density.

Related

Say it back

How would you explain this to someone you love?

Two or three sentences, just as you’d say it. Gale reflects back what you focused on — a mirror, not a quiz.

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

Risk-reducing drugs: symptoms that need attention

  • —Sudden swelling, pain, warmth, or redness in one leg, or chest pain and shortness of breath, can signal a blood clot and is a reason to seek urgent medical care.
  • —Any new abnormal vaginal bleeding or spotting, especially after menopause, is a reason to seek clinician review because it can indicate a uterine problem.
  • —A new breast lump, one-sided breast change, or nipple change is a reason to seek clinician review.
  • —Sudden vision changes or a severe, persistent headache is a reason to seek clinician review.

Signs of a blood clot, such as sudden swelling or pain in one leg, chest pain, or shortness of breath, need same-day emergency care; call 911 or go to the nearest emergency room.

This article is general health education, not medical advice. Choosing between tamoxifen and raloxifene depends on your personal breast cancer risk, menopausal status, and health history, and should be decided with a gynecologist, breast specialist, or genetic counselor.

References

  1. 1.Vogel VG, Costantino JP, Wickerham DL, et al. / NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 (2006). Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. doi:10.1001/jama.295.23.joc60074 ✓The STAR (P-2) head-to-head trial in postmenopausal women: raloxifene was about as effective as tamoxifen against invasive breast cancer, with fewer blood clots and fewer uterine cancers.
  2. 2.Fisher B, Costantino JP, Wickerham DL, et al. / National Surgical Adjuvant Breast and Bowel Project (NSABP) P-1 Study (1998). Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. Journal of the National Cancer Institute. doi:10.1093/jnci/90.18.1371 ✓The NSABP P-1 trial enrolled premenopausal and postmenopausal women and set tamoxifen's prevention benchmark of about a 49% reduction in invasive breast cancer.
  3. 3.Ettinger B, Black DM, Mitlak BH, et al. / Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators (1999). Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA. doi:10.1001/jama.282.7.637 ✓The MORE trial showed raloxifene reduces vertebral (spinal) fracture risk in postmenopausal women with osteoporosis; supports raloxifene's added bone benefit.
  4. 4.American College of Obstetricians and Gynecologists (2017). Practice Bulletin Number 179: Breast Cancer Risk Assessment and Screening in Average-Risk Women. Obstetrics & Gynecology. doi:10.1097/AOG.0000000000002158 ✓Breast cancer risk assessment with validated models to identify candidates for risk-reducing therapy; supports the shared-decision and candidacy framing.
  5. 5.National Cancer Institute (2024). BRCA Gene Changes: Cancer Risk and Genetic Testing Fact Sheet. National Cancer Institute (NCI), NIH. link ✓BRCA changes and family history raise breast cancer risk; supports the point that inherited risk shifts the candidacy calculation.

5 sources, numbered by first appearance. General health information, not medical advice. AI-assisted editorial content — every citation independently verified. Editorial policy

← Back to the health library